Lung Cancer | Specialty

Dr. Socinski on Recommendations for Molecular Testing in Lung Cancer

March 31st 2020

Mark A. Socinski, MD, discusses his recommendations for conducting molecular testing in lung cancer.

Dr. Chen on the Impact of the Pivotal IMpower133 Trial on SCLC

March 31st 2020

Hui-Zi Chen, MD, PhD, discusses how the IMpower133 trial has helped to propel the field of small-cell lung cancer forward.

RET Inhibition Research: Next Steps

March 30th 2020

The Future of RET Inhibition in Clinical Practice

March 30th 2020

RET Inhibitors in Development

March 30th 2020

Effect of NGS Wait Time on Decision Making

March 30th 2020

Targeted Therapy Benefit for Actionable Mutations

March 30th 2020

The Impact of Upfront NGS Testing on Overall Outcomes

March 30th 2020

The Importance of NGS Testing in NSCLC

March 30th 2020

Multikinase TKI Toxicity Profile

March 30th 2020

The Role of Multikinase TKIs for NSCLC

March 30th 2020

MOA and Rationale for RET Inhibitor Development

March 30th 2020

The Importance of Targeting RET in NSCLC

March 30th 2020

Trastuzumab Deruxtecan Shows Promise Beyond Breast and Gastric Tumors

March 30th 2020

Fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody­–drug conjugate, demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types.

FDA Approves Durvalumab for Frontline Small Cell Lung Cancer

March 30th 2020

The FDA has approved durvalumab for the first-line treatment of adult patients with extensive-stage small cell lung cancer for use in combination with standard-of-care chemotherapy, which includes etoposide plus either carboplatin or cisplatin.

Tepotinib Approved in Japan for MET-Positive NSCLC

March 25th 2020

Tepotinib (Tepmetko) has been approved in Japan for the treatment of patients with non–small cell lung cancer harboring MET exon 14 skipping alterations.

Expert Perspectives in the Evolving ALK+ NSCLC Paradigm

March 24th 2020

In a wide-ranging discussion, Alexander Drilon, MD; Julia Rotow, MD; Thomas E. Stinchcombe, MD; and Ashish Saxena, MD, PhD, provide expert insight on developments in ALK-positive non–small cell lung cancer.

Plasma-Based TMB May Predict Pembrolizumab Response in NSCLC

March 24th 2020

Charu Aggarwal, MD, MPH, discusses the design and findings of an analysis examining the role of TMB as a predictive biomarker for pembrolizumab-based therapy in NSCLC.

Expert Shares Insight on Utility of Immunotherapy and Targeted Agents Across NSCLC

March 24th 2020

Gregory A. Otterson, MD, discusses the utility of immunotherapy in squamous non–small cell lung cancer and targeted the evolution of targeted therapy in biomarker-driven disease.

SCLC Paradigm Advances With Immunotherapy, Integration of Rapid Research Autopsies

March 23rd 2020

Hui-Zi Chen, MD, PhD, discusses the use of immunotherapy in ES-SCLC and the work being done to identify mechanisms of resistance to frontline therapy.